Sacituzumab Tirumotecan Plus Immunotherapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

NCT07686588 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Recurrent or Metastatic Head and Neck Carcinoma

Interventions

DRUG: Sacituzumab Tirumotecan Plus Immune Checkpoint Inhibitor

Sponsor

Biying Chen